eksperimental vaksin Mers menunjukkan janji dalam studi hewan--T-REC-komunitas reptil-semarang--KSE-komunitas satwa eksotik

SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

.................


T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA


More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
..................................
KSE – KOMUNITAS SATWA EKSOTIK – EXOTIC PETS COMMUNITY-- INDONESIA
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI   :  089617123865-08995557626

.........................

eksperimental  vaksin Mers menunjukkan janji dalam studi hewan

Date:

July 28, 2015

Source:

NIH/National Institute of Allergy and Infectious Diseases

Summary:

Sebuah rejimen dua langkah vaksin eksperimental terhadap Mers respon imun pada tikus dan kera rhesus macaques . Tikus divaksinasi diproduksi luas menetralisir antibodi terhadap beberapa strain dari coronavirus mer , sementara kera yang divaksinasi dilindungi dari kerusakan paru-paru yang parah saat kemudian terkena Mers- CoV . Temuan menunjukkan bahwa pendekatan saat ini, di mana desain vaksin dipandu oleh pemahaman tentang struktur komponen virus dan interaksi mereka dengan sel inang , member harapan  untuk mengembangkan  rejimen vaksin Mers manusia  yang sama 

................ Saat ini, vaksin tidak berlisensi tersedia untuk mer , penyakit yang pertama kali muncul pada tahun 2012. Sebuah wabah di Republik Korea yang dimulai pada bulan Mei telah menyebabkan lebih dari 180 infeksi dikonfirmasi , termasuk 36 kematian , hingga 15 Juli serta gangguan sosial yang luas 

Tim peneliti dipimpin oleh Barney S. Graham , MD , Ph.D. , Wing - Pui Kong , Ph.D. , dan rekan-rekannya di Institut Nasional Alergi dan Penyakit Menular ' Vaksin Research Center . Para peneliti menggunakan informasi struktural tentang protein virus yang disebut spike ( S ) glikoprotein , yang menggunakan Mers - CoV masuk sel , untuk merancang sejumlah vaksin eksperimental bahwa mereka diberikan kepada tikus dalam rejimen dua langkah yang melibatkan awal " priming " injeksi diikuti beberapa minggu kemudian dengan sama atau " penguat " vaksin yang berbeda .....more

Experimental
MERS vaccine shows promise in animal studies

Date:

July 28, 2015

Source:

NIH/National Institute of Allergy and Infectious Diseases

Summary:

A two-step regimen of experimental vaccines against MERS prompted immune
responses in mice and rhesus macaques. Vaccinated mice produced broadly
neutralizing antibodies against multiple strains of the MERS coronavirus, while
vaccinated macaques were protected from severe lung damage when later exposed
to MERS-CoV. The findings suggest that the current approach, in which vaccine
design is guided by an understanding of structure of viral components and their
interactions with host cells, holds promise for developing a similar human MERS
vaccine regimen.

...................

A two-step regimen of experimental vaccines against Middle East respiratory
syndrome (MERS) prompted immune responses in mice and rhesus macaques, report
National Institutes of Health scientists who designed the vaccines. Vaccinated
mice produced broadly neutralizing antibodies against multiple strains of the
MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from
severe lung damage when later exposed to MERS-CoV. The findings suggest that
the current approach, in which vaccine design is guided by an understanding of
structure of viral components and their interactions with host cells, holds
promise for developing a similar human MERS vaccine regimen.

Currently, no licensed vaccines are available for MERS, a disease that
first appeared in 2012. An outbreak in the Republic of Korea that began in May
has caused more than 180 confirmed infections, including 36 deaths, through
July 15 as well as widespread social disruption.

The research team was led by Barney S. Graham, M.D., Ph.D., Wing-Pui Kong,
Ph.D., and colleagues at the National Institute of Allergy and Infectious
Diseases' Vaccine Research Center. The investigators used structural
information about a viral protein called the spike (S) glycoprotein, which
MERS-CoV uses to enter cells, to design a number of experimental vaccines that
they administered to mice in a two-step regimen involving an initial
"priming" injection followed several weeks later by the same or a
different "booster" vaccine.

The three prime-boost regimens that elicited the most robust immune
responses in mice were then tested in groups of macaques and were found to
elicit similar immune system responses. A separate group of 18 macaques (12
vaccinated, six unvaccinated) were exposed to MERS-CoV 19 weeks after the
vaccinated animals received the boost injection. Although macaques do not
develop overt MERS disease, the researchers observed that unvaccinated animals
experienced lung abnormalities indicative of pneumonia that were more profound
and longer lasting than those seen in the vaccinated animals. The team is now
working on refining the vaccine candidates and may eventually test a
second-generation vaccine candidate in clinical trials.







Story Source:

The above post is reprinted from materials provided byNIH/National
Institute of Allergy and Infectious Diseases.Note: Materials
may be edited for content and length.







Journal Reference:

1.   
Lingshu Wang, Wei Shi, M. Gordon Joyce, Kayvon Modjarrad, Yi Zhang, Kwanyee
Leung, Christopher R. Lees, Tongqing Zhou, Hadi M. Yassine, Masaru Kanekiyo,
Zhi-yong Yang, Xuejun Chen, Michelle M. Becker, Megan Freeman, Leatrice Vogel,
Joshua C. Johnson, Gene Olinger, John P. Todd, Ulas Bagci, Jeffrey Solomon,
Daniel J. Mollura, Lisa Hensley, Peter Jahrling, Mark R. Denison, Srinivas S.
Rao, Kanta Subbarao, Peter D. Kwong, John R. Mascola, Wing-Pui Kong, Barney S.
Graham. Evaluation of candidate vaccine approaches for MERS-CoV. Nature
Communications, 2015; 6: 7712 DOI: 10.1038/ncomms8712

http://www.sciencedaily.com/releases/2015/07/150728120149.htm

Share this: